Market Trends of Global Pancreatic Cancer Therapeutics and Diagnostics Industry
This section covers the major market trends shaping the Pancreatic Cancer Therapeutics & Diagnostics Market according to our research experts:
The Chemotherapy Segment is Expected to Witness a Major Share in the Studied Market Over the Forecast Period
Chemotherapy is one of the main cancer treatments that kill pancreatic cancer cells by preventing them from growing and dividing. These drugs are systemic treatments; the drugs travel through the bloodstream and damage cancer cells throughout the body. Unfortunately, chemotherapy can damage some healthy cells and cause major side effects. Chemotherapy may shrink and/or prevent the growth of pancreatic tumors. According to the American Cancer Society, the chemotherapy drugs used to treat pancreatic cancer include Gemcitabine (Gemzar), 5-fluorouracil (5-FU), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Albumin-bound paclitaxel (Abraxane), Capecitabine (Xeloda), Cisplatin, Paclitaxel (Taxol), Docetaxel (Taxotere), and Irinotecan liposome (Onivyde).
Since the 1990s, the chemotherapy drug gemcitabine (Gemzar) has been the backbone of treating people with pancreatic cancer that can be removed with surgery (resectable). Traditionally, gemcitabine has been given as adjuvant chemotherapy after the patient has recovered from the surgery, which, for many patients, is a grueling procedure known as the Whipple procedure. More recently, gemcitabine is sometimes combined with the chemotherapy drug capecitabine (Xeloda). Chemotherapy may also be given alone or combined with surgery, targeted therapy, immunotherapy, and/or radiation. When chemotherapy is given in combination with radiation, a low dose of chemotherapy is typically used. The chemotherapy drugs most commonly used in conjunction with radiation therapy are fluorouracil (5-FU) and gemcitabine (Gemzar). 5-FU is used most often since there is more experience using this drug in combination with radiation, and there are fewer side effects.
In March 2020, the Pancreatic Cancer Collective, the strategic partnership of the Lustgarten Foundation and Stand Up To Cancer (SU2C), was awarded up to USD 16 million to four teams of top researchers, including a team at Dana-Farber Cancer Institute, as part of its New Therapies Challenge Grants, the American Association for Cancer Research (AACR), and Scientific Partner of SU2C. Nearly USD 4 million in funding is available to help support three pancreatic cancer clinical trials testing DNA repair inhibitors combined with chemotherapy. Thus, due to the surging demand for effective treatment options for pancreatic cancers, the studied segment is expected to witness significant growth over the forecast period.
North America Dominated the Overall Market and is Expected to Retain its Dominance
The United States is expected to retain its significant market share due to the rising incidence of pancreatic cancers, supportive reimbursement policies, and high healthcare spending.
As per a 2018 publication in the MedCrave Gastroenterology and Hepatology journal, pancreatic cancer was the ninth most frequent cancer, despite its moderate incidence. It was expected to be among the second-deadliest cause of cancer by 2030. Also, according to the GLOBOCAN 2020 report, about 56,654 new cases of pancreatic cancer were reported in 2020. Moreover, approximately 47,683 deaths due to pancreatic cancer were reported in the United States. The USFDA is also taking steps to enhance the growth of the pancreatic cancer therapeutics and diagnostic market by approving drugs in the clinical phase, thereby accelerating clinical developments. Companies and research organizations are investing in R&D. Thus, the market is expanding quickly. For instance, in 2020, ERYTECH's lead product candidate, eryaspase, received the fast track designation by the FDA due to the urgent need for potential new treatment options for patients with second-line metastatic pancreatic cancer in the country. Such product approvals by the FDA are expected to lift the overall market.
In 2020, NANOBIOTIX announced its first phase I trial with NBTXR3 in Pancreatic Cancer, which is safe to proceed as per the US FDA. The trial was co-developed with Nanobiotix, and MD Anderson is the sponsor and executor of the trial. These clinical trials' positive outcomes will result in a new treatment, positively influencing the regional market growth. Thus, owing to the factors mentioned above, the studied market is anticipated to register significant growth over the forecast period in the region.
